Renal denervation market is expected to rising from USD 200 million in 2017 to USD 11,488.51 million in 2030, at a solid CAGR of 38.60% over the forecast period
Renal Denervation Market Overview:
Over the 2022-2030 projection periods, the renal denervation market is predicted to grow at a respectable CAGR of 38.60 percent, with the industry's value growing from USD 200 million in 2017 to USD 11.48 billion in 2030. The growing prevalence of hypertension throughout the world is driving the renal denervation market. According to the CDC, the prevalence of hypertension among persons aged 20 and up was close to 26% in 2000.
Over the next 10 years, the prevalence of hypertension is expected to rise by 5.2 percent, making it a major worry for the global healthcare industry. Developed nations have been aggressive in implementing efforts to combat and minimize the prevalence of hypertension among their populations, resulting in rising levels of hypertension. Renal denervation is a minimally invasive treatment for resistant hypertension. To lower sympathetic activity in the kidney and blood pressure, RF or ultrasonic ablation of nerves in the renal artery is used.
Boston Scientific Corporation (Boston Scientific or 'the firm') is a maker of interventional medical equipment. Drug-eluting coronary stent systems, percutaneous coronary interventions, intravascular catheter-directed ultrasonography imaging catheters, fractional flow reserve, and systems and equipment utilized in coronary arteries and heart chambers are among the company's offerings. The company's products and services are available to clinics, outpatient facilities, hospitals, and medical offices all around the world. Boston Scientific is based in Marlborough, Massachusetts, in the United States.
The RADIANCE-II pivotal study of ReCor Medical's Paradise Ultrasound Renal Denervation (uRDN) System to treat hypertension has concluded subject enrollment. The Paradise uRDN System was created by the business as a minimally invasive treatment for treating hyperactive nerves leading to the kidney. The RADIANCE-II pivotal study is aimed to assess the platform's ability to treat uncontrolled hypertension in individuals using zero to two antihypertensive oral medicines.
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, Technology, and End use|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||